Future Outlook of Expedited Pathways in 2026
Continued Growth in Expedited Approvals
The use of expedited pathways such as Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval is expected to continue growing in 2026 and beyond, particularly in oncology, rare diseases, metabolic disorders, and precision medicine. Rising unmet medical needs, strong investor pressure for faster commercialisation, and increasing scientific innovation are driving more companies to pursue these pathways. FDA’s 2026 novel drug approvals already show strong momentum, with multiple approvals across rare diseases, obesity, HIV, and speciality care by April alone, including Foundayo, Avlayah, and Loargys. This trend suggests that expedited programs will remain central to regulatory strategy for both large pharma and biotech companies.
Expansion of Gene Therapies
Gene therapies are expected to become one of the fastest-growing areas within expedited approvals due to their potential to provide one-time, disease-modifying treatment for severe and inherited disorders. Because many gene therapies target rare diseases with limited treatment options, they are strong candidates for Breakthrough Therapy Designation, Priority Review, and Accelerated Approval.
A strong 2026 example is Otarmeni (lunsotogene parvec-cwha), an adeno-associated virus (AAV)-based gene therapy approved in April 2026 for genetic OTOF-related hearing loss under accelerated approval. This reflects how the FDA is increasingly supporting transformative therapies with faster regulatory pathways.
Expansion of Cell Therapies
Cell therapies, particularly CAR-T therapies, stem cell-based treatments, and regenerative medicines, are also expected to see broader use of expedited pathways. These therapies often address life-threatening diseases where traditional treatment options are limited, making them ideal candidates for accelerated regulatory review.
The FDA’s continued support for regenerative medicine and oncology innovation suggests stronger future growth in cell therapy approvals, especially as real-world evidence and long-term durability data improve. The agency’s broader focus on faster innovation and reduced administrative delays supports this expansion.
Stricter Post-Marketing Requirements Expected
As more drugs receive earlier approvals based on surrogate endpoints or limited datasets, stricter post-marketing requirements are becoming increasingly necessary. Regulators are expected to enforce stronger confirmatory trial timelines, more frequent sponsor reporting, clearer labelling of clinical uncertainty, and faster withdrawal mechanisms for therapies that fail to confirm benefit.
The 2026 ICER white paper highlighted that the FDA now requires confirmatory trials to be underway at the time of accelerated approval, and sponsors must provide updates every 180 days rather than annually. This signals a major shift toward stronger lifecycle accountability after approval.
Potential Regulatory Reforms to Balance Speed vs. Safety
Future regulatory reforms are likely to focus on balancing faster patient access with stronger evidence standards and patient protection. Policymakers are increasingly pushing for better surrogate endpoint selection, mandatory advisory committee reviews, evidence-quality scoring systems, and improved transparency around approval decisions.
Reuters reported in April 2026 that ICER recommended reforms such as stronger evidence scoring, value-based pricing alignment, and greater enforcement of confirmatory studies to improve trust in the Accelerated Approval pathway. At the same time, the FDA launched a real-time clinical trial monitoring pilot program in April 2026 to speed approvals while improving oversight, showing how future reform may combine both faster review and stronger regulatory control.
